Impact of clinical pharmacist-led interventions on denosumab adherence
Abstract
Pharmacist-led interventions significantly improved denosumab adherence in patients with osteoporosis at an academic medical center, reducing non-adherence from 20.8 to 4.9%. This quality improvement initiative included pharmacist-led medication counseling and laboratory monitoring, highlighting the effectiveness of pharmacist-physician collaboration in preventing rebound-associated vertebral fractures and enhancing patient outcomes.
Background: Interrupting or delaying denosumab beyond 7 months (210 days) from the last injection leads to transient increase in bone turnover known as rebound phenomenon, resulting in rapid loss of bone density and increased risk of vertebral fracture(s), now known as rebound-associated vertebral fractures (RAVF). Numerous studies suggest that clinical pharmacist participation in chronic disease state management leads to an increase in medication adherence and positive clinical outcomes. We evaluated the impact of a clinical pharmacist intervention on adherence to optimal denosumab timing for patients with osteoporosis.
Methods: The model for improvement was used to design and evaluate this quality improvement project. This study analyzed 143 patients receiving denosumab therapy in an osteoporosis clinic every 6 months for the indication of osteoporosis. At baseline, 21% of patients receiving denosumab did not receive the medication at optimal time intervals for clinical effectiveness. An administration was considered correct or on time if…
Read the paper
Related studies
- Effectiveness of Bisphosphonates and Denosumab on Risk of Vertebral Fractures in Prostate Cancer Patients Under Androgen Deprivation Therapies: A Real-World Prospective Study
- Osteoporosis-related fractures after spinal cord injury: a retrospective study from Brazil
- Serum 25-hydroxyvitamin D, parathyroid hormone, and mortality in older men
- Lack of Association between Vitamin D Insufficiency and Cardiovascular or Fracture Risk: A UK Biobank Study
- Muscle strength and body composition are clinical indicators of osteoporosis
- Incidence of bone protection and associated fragility injuries in patients with proximal femur fractures
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.